Riccioni T, Cirielli C, Wang X, Passaniti A, Capogrossi M C
Gene Therapy Unit, Laboratory of Cardiovascular Science, National Institutes of Health, Baltimore, MD, USA.
Gene Ther. 1998 Jun;5(6):747-54. doi: 10.1038/sj.gt.3300681.
Gene therapy with the tumor suppressor gene p53 induces cancer cell apoptosis in vitro and in vivo and inhibits tumor growth in nude mice. We hypothesized that, in addition to cancer cell apoptosis, a replication-deficient adenovirus vector which carries the cDNA for human wild-type p53 (AdCMV.p53) may also modulate endothelial cell function and inhibit angiogenesis. Human umbilical vein endothelial cells (HUVEC) were infected at different multiplicities of infection (MOI) with either AdCMV.p53, the control vector AdCMV.null or were not infected. Western blot analysis showed p53 overexpression up to 7 days after infection with AdCMV.p53. HUVEC proliferation was either not affected (20 and 50 MOI) or inhibited to comparable levels (100 MOI; P < 0.05) in AdCMV.p53- and AdCMV.null-infected versus uninfected cells. HUVEC differentiation into capillary-like structures on reconstituted basement membrane proteins (Matrigel) was assessed 48 h after infection (100 MOI). After 18 h on Matrigel the capillary-like network formed by AdCMV.p53-infected HUVEC was less extensive than that formed by both AdCMV.null-infected and uninfected control cells (P < 0.05 versus either control). In contrast, conditioned medium from AdCMV.p53-infected HUVEC did not modulate endothelial cell differentiation on Matrigel. The effect of AdCMV.p53 on angiogenesis in vivo was assessed by injecting this vector subcutaneously in mice; 3 days later Matrigel containing basic fibroblast growth factor (bFGF) was injected at the same site. In other experiments AdCMV.p53 was injected simultaneously with an Ad vector coding for vascular endothelial growth factor (AdCMV.VEGF165) into the rat perirenal fat tissue. AdCMV.p53 significantly inhibited neovascularization induced by bFGF within the Matrigel plugs (P < 0.05) or by AdCMV.VEGF165 in the fat tissue (P < 0.05). Thus, the anti-angiogenic effect of Ad-mediated wild-type p53 overexpression may contribute to the ability of this viral vector to inhibit tumor growth.
用肿瘤抑制基因p53进行基因治疗可在体外和体内诱导癌细胞凋亡,并抑制裸鼠肿瘤生长。我们推测,除了癌细胞凋亡外,携带人野生型p53 cDNA的复制缺陷型腺病毒载体(AdCMV.p53)还可能调节内皮细胞功能并抑制血管生成。用人脐静脉内皮细胞(HUVEC)分别以不同的感染复数(MOI)感染AdCMV.p53、对照载体AdCMV.null或不进行感染。蛋白质免疫印迹分析显示,感染AdCMV.p53后长达7天p53均有过表达。在AdCMV.p53和AdCMV.null感染组与未感染组的细胞中,HUVEC增殖要么未受影响(20和50 MOI),要么受到抑制且达到相当水平(100 MOI;P<0.05)。感染后48小时(100 MOI)评估HUVEC在重组基底膜蛋白(基质胶)上分化为毛细血管样结构的情况。在基质胶上培养18小时后,AdCMV.p53感染的HUVEC形成的毛细血管样网络不如AdCMV.null感染组和未感染组的对照组细胞形成的网络广泛(与任一对照组相比,P<0.05)。相反,AdCMV.p53感染的HUVEC的条件培养基并未调节基质胶上的内皮细胞分化。通过在小鼠皮下注射该载体来评估AdCMV.p53在体内对血管生成的影响;3天后在同一部位注射含碱性成纤维细胞生长因子(bFGF)的基质胶。在其他实验中,将AdCMV.p53与编码血管内皮生长因子的腺病毒载体(AdCMV.VEGF165)同时注射到大鼠肾周脂肪组织中。AdCMV.p53显著抑制了基质胶栓内由bFGF诱导的新生血管形成(P<0.05)或脂肪组织中由AdCMV.VEGF165诱导的新生血管形成(P<0.05)。因此,Ad介导的野生型p53过表达的抗血管生成作用可能有助于该病毒载体抑制肿瘤生长的能力。